Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ABBV

AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar

Alvotech Holdings S.A. has

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute

Here's a roundup of top developments in the biotech space over the last 24 hours.

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.52% on an annualized basis.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Looking At AbbVie's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

AbbVie Files Imbruvica US Application For Pediatric Patients with Chronic Graft Versus Host Disease

AbbVie Inc (NYSE: ABBV) has

Where AbbVie Stands With Analysts

Over the past 3 months, 9 analysts have published their opinion on AbbVie (NYSE:ABBV) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

What Are Whales Doing With AbbVie

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Unstoppable Healthcare Stocks to Buy and Hold in 2022

3 Unstoppable Healthcare Stocks to Buy and Hold in 2022

The healthcare industry has ridden a promising wave of innovation and investments over the past few years. Also, with continuing acceleration in the digital transformation of healthcare and breakthrough developments, with healthcare expenditure expected to grow in the coming years, the industry’s prospects look bright. Therefore, we think healthcare stocks…

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.85% on an annualized basis.

Forget AstraZeneca, Buy These 4 Pharmaceutical Stocks Instead

Forget AstraZeneca, Buy These 4 Pharmaceutical Stocks Instead

Despite the rising demand for COVID-19 vaccines and other pharmaceutical products, AstraZeneca (AZN) has failed to deliver impressive earnings in its last quarter. While its recent drug launches are expected to do well in the long run, the consensus earnings estimate for the company in the current quarter indicates tepid…

Check Out What Whales Are Doing With ABBV

Check Out What Whales Are Doing With ABBV

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 22 strange trades.

3 Warren Buffett Stocks to Buy in February: DaVita, Bristol Myers Squibb, and AbbVie

3 Warren Buffett Stocks to Buy in February: DaVita, Bristol Myers Squibb, and AbbVie

Warren Buffett’s value investing strategy has paid off, as its investment firm Berkshire Hathaway (BRK.A) has outperformed the broader market. Recently, the billionaire has become worther than Meta Platforms (FB) founder Mark Zuckerberg. Hence, we believe that the Berkshire Hathaway holdings AbbVie (ABBV), Bristol-Myers Squibb (BMY), and DaVita (DVA) might…

AbbVie Expects Solid FY22 As Botox, Skyrizi Power Q4 Earnings

AbbVie Expects Solid FY22 As Botox, Skyrizi Power Q4 Earnings

AbbVie Inc (NYSE: ABBV) reports

AbbVie: Q4 Earnings Insights

AbbVie: Q4 Earnings Insights

AbbVie (NYSE:ABBV) reported its Q4 earnings results on Wednesday, February 2, 2022 at 07:44 AM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100’s of premium titles.
One news app.

Earnings Outlook For AbbVie

AbbVie (NYSE:ABBV) is set to give its latest quarterly earnings report on Wednesday, 2022-02-02. Here's what investors need to know before the announcement. Analysts estimate that AbbVie will likely report an Earnings Per Share (EPS) of $3.28.

AbbVie Whale Trades For January 25

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Analyst Ratings For AbbVie

Within the last quarter, AbbVie (NYSE:ABBV) has observed the following analyst ratings:

4 Stocks to Buy if You Think Inflation is Peaking

Annual inflation has hit multi-year highs in December. Benchmarks are currently in a correction mode, and economists expect the Fed to come up with a rate hike very soon. Given this volatile environment, the mega-cap tech stocks Microsoft (MSFT) and Alphabet (GOOGL) might be an ideal hedge against inflation. Also,…

Get all your
news in one place.

100’s of premium titles.
One news app.

This Is What Whales Are Betting On AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 19 strange trades.

$1000 Invested In This Stock 5 Years Ago, Would Be Worth This Much

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 2.43% on an annualized basis.

3 Buy-Rated Stocks Yielding More than 4%

As the stock market is expected to remain volatile owing to the anticipated interest rate hikes to control inflation, it could be wise to bet on fundamentally strong dividend-yielding stocks AbbVie (ABBV), Philip Morris (PM), and Vector Group (VGR) for securing a steady income stream. These stocks are rated ‘Buy’…

Even After Their Recent Sell-Off, Stay Away From These 3 Overvalued Electric Vehicle Stocks

The benchmark indexes witnessed a bull run in 2021, with numerous stocks soaring to record high price levels which were not in sync with their fundamentals. Shares of Electric vehicle companies Rivian Automotive (RIVN), Lucid Group (LCID), and NIO (NIO) hit their record highs as EVs have been dubbed as…

FDA Approves AbbVie's Upadacitinib For Refractory Atopic Dermatitis In Patients 12 Years & Older

1 … 8 9 10 11

People

Mark Zuckerberg

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Berkshire Hathaway

Johnson & Johnson (

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play